Objective: To investigate the feasibility of HBV DNA vaccines.
目的：探讨HBV核酸免疫的可行性。
Three patients had 1-2 episodes of transiently detectable HBV DNA.
三名病人曾有过1-2次被检测到HBV DNA，但仅为暂时性的。
CDK4 amplification could be correlated with HBV DNA integration and the progression of HCC.
CDK4的扩增可能与HBV -DNA的整合以及肝癌的进展有关。
Moreover, digoxigenin-HBV DNA probe was highly specific , stable and of low back-ground colour.
经过试验观察还证明，此探针检测HBV DNA的特异性高，重复性好，背景显色也较低。
Prior to transplantation, patients with detectable serum HBV DNA received lamivudine 100 mg daily.
移植前，血清可检出HBV DNA的患者进行每日100mg拉米夫定的治疗。
Results The sensitivity, specificity and accurate of HBV DNA detection are all very high. Conclusion That can be used widely.
结果检测HBV DNA灵敏度、特异性及定量分析精确度均十分理想。
Objective To explore the sensitivity difference between fluorescent quantity PCR (FQ-PCR) and routine PCR for HBV DNA detection.
目的探讨荧光定量聚合酶链反应(FQ PCR)与常规聚合酶链反应检测乙型肝炎病毒(HBV)敏感性的差异。
Objective To evaluate the efficacy of adefovir dipivoxil(ADV) on chronic hepatitis B(CHB) patients with HBV DNA breakthrough(>1.
目的观察阿德福韦酯挽救治疗拉米夫定治疗后HBV DNA突破患者的疗效。
Objective To explore the clinical significance and the relationship between the HBV DNA quantity and the quantity testing of HBVM.
目的探讨定量检测乙型肝炎病毒血清标志物（HBVM）与（HBV DNA）定量之间的关系及临床意义。
Piezoelectric quartz crystal HBV DNA biosensor is easy to operate, convenient and accurate, which has a good future in clinical detection.
压电石英晶体传感器操作方便、省时，且具有较好的准确度，在临床诊断中有很好的前景。
Weekly assessment of serum antigen levels, HBV viral proteins and extracellular HBV DNA were conducted for the duration of the 56-day study.
在为期56天的研究中，每周均对血清抗原水平进行评估，持续监测HBV病毒蛋白和细胞外hBVDNA水平。
CONCLUSIONS HBV DNA extracted from clinical samples were directly detected using PNA biosensor and PCR amplification was successfully bypassed.
结论利用肽核酸生物传感器成功地绕过了PCR扩增而直接检测出了临床标本中的HBV基因组dna。
Objective:To investigate the relationship among serum HBV DNA quantification, hepatitis clinical changes and HBV markers in hepatitis patients.
目的：探讨乙型肝炎病毒DNA定量与肝炎临床的转归及血清标志物的关系。
Results HBV DNA positive of blood is apparently higher than it in serum, HBV DNA content in liver tissue is apparently higher than it in blood.
结果慢性乙型肝炎患者肝组织HBV DNA检出率明显高于血清内，肝组织内HBV DNA含量明显高于血液内。
Objective To quantify the HBV DNA in saliva of chronic hepatitis B patients and to study its relation to the periodontal status of the patients.
目的观察肝炎患者中不同口腔卫生指标对唾液HBV DNA状况的影响，探讨牙周健康状况在乙型肝炎传播流行中的意义。
Objective to observe the therapeutic effect of autologous cytokine-induced killer cells (CIK) on HBV DNA positive patients with liver cirrhosis.
目的观察自体细胞因子诱导杀伤细胞(CIK细胞)治疗HBV DNA阳性肝硬化患者的近期疗效。
The best indicators of sustained virologic response are low pre-treatment serum HBV DNA titers and elevated alanine aminotransferase (ALT) levels.
持续性病毒学应答的最佳指标是较低的治疗前血清hbv DNA滴度和较高的谷丙转氨酶(ALT)水平。
Exploratory analysis revealed that high levels of pretreatment HBV DNA had a significantly higher incidence of severe hepatitis during chemotherapy.
探索性分析提示化疗前的高hbv DNA水平患者在化疗期间将明显有急性肝炎的高发生率。
We also found that a previously used method to detect cytosine deaminated DNA, termed 3DPCR, overestimates the amount and frequency of edited HBV DNA.
研究还发现，以前用来检测DNA胞嘧啶脱氨基的被称为3D-PCR 的方法高估了编辑HBV DNA的数量和频率。
Treating with nucleosides plus ALSS could accelerate the amelioration of liver function, shorten course of disease, decrease mortality and HBV DNA level.
核苷类似物联合人工肝治疗可加快肝功能好转，缩短病程，降低病死率，降低血清HBV DNA水平。
To investigate the change of HBV DNA in children with hepatitis B. HBVM and HBV DNA were detected by microparticle enzyme immunoassay (MEIA) and PCR respectively.
了解小儿乙型肝炎病毒(HBV DNA)复制水平的变化及其临床意义。采用微粒子酶免分析法(MEIA)检测HBVM，荧光定量pcr法检h BV DNA。
Conclusion the combination detection of YMDD variants, HBV DNA and HBV serum markers may define HBV reinfection after liver transplantation in the patients with hepatitis b.
结论乙型肝炎肝硬化患者肝移植后预防乙型肝炎复发应采用HBV DNA、YMDD变异及血清标志物联合检测。
Objective: to establish a method of HBV genotyping by directly gene sequencing of HBV DNA s gene and to discuss the relationship between the HBV genotype and clinical status.
目的：建立乙型肝炎病毒S基因直接测序分型方法，初步探讨HBV基因分型与临床之间的关系。
Methods Serum samples from 188 chronic hepatitis B patients with lamivudine therapy were collected and quantitatively tested with real-time PCR for HBV DNA and YMDD mutations.
方法将接受拉米夫定治疗的188例患者根据治疗时间进行分组，采用实时荧光PCR方法定量检测各组患者血清HBV DNA水平和酪氨酸-甲硫氨酸-天冬氨酸-天冬氨酸（YMDD）变异。
Conclusions the relatively high ALT level, low HBV DNA ration and early virus response are the major factors that affect the curative effect of lamivudine in treating chronic hepatitis B.
结论治疗前较高的ALT水平，较低的HBV DNA定量值及出现早期病毒学应答是影响拉米夫定治疗慢性乙型肝炎疗效的主要因素。
Methods HBV genotypes were detected by polymerase chain reaction (PCR) and restriction fragment length polymorphism analysis (RFLP) in 136 HBV DNA positive patients who were born in Shanghai.
方法采用聚合酶链反应-限制性片段长度多态性分析(PCR - RFLP)检测136例HBV DNA阳性的上海籍HBV感染者的基因型。
To elucidate those, a total of 743 successive in-patients with biopsy-proved CHB were included to analyse correlation of HBV DNA levels with alanine transaminase (ALT) values and liver histology.
本文对经肝活检证实的743例CHB住院病人的丙氨酸转氨酶（ALT）、病毒定量、肝组织病理分级和分期及其相互关系进行对比研究。
Objective to investigate the existence status of HBV DNA in the peripheral blood lymphocytes (PBL) of chronic HB patients and to study its correlation with the state of HBV infection in the liver.
目的探讨慢性乙型肝炎患者外周血淋巴细胞内hbv存在状态及其与肝内带毒状况的相关性。
The HBV markers and HBV DNA in poultry sera, Yolk and bovine milk whey were detected by reversed passive hemagglutination assay (RPHA), enzyme immunoassay (EIA) and polymerase chain reaction (PCR).
应用反向间接血凝试验（RPHA）、酶免疫测定（EIA）和聚合酶链反应（PCR）测定了家禽血清、卵黄和牛乳清中HBV标志物及人HBV-DNA。
ObjectiveTo study clinical meaning of new DNA chip technique in detecting the mutation of HBV-DNA , and to offer testimony for clinical diagnosis and treatment.
应用新型基因芯片研究乙肝病毒多点基因变异在慢性乙肝患者中的意义，为临床诊断和治疗提供依据。
应用推荐